The biosimilar market is emerging and biosimilar antibodies are now being developed in order to address treatment to conditions that are being treated by their original and biological therapy. There are very few biosimilars that have received approval from the EMA, and only has one received approval from the FDA. In a review article, scientists used the clinical advancements concerning data from a biosimilar drug to explore the benefits and risks of these cost-effective treatment options that remain unfamiliar to the public. The article is focused on the first biosimilar monoclonal antibody approved in Europe and was published in Immunotherapy, a peer-reviewed online title.
“While there is growing interest in biosimilars and their potential to reduce the cost of treatment for a number of debilitating diseases, clinicians and patients alike still have some questions,” said Henry Ireland who is the Drug Evaluations Commissioning Editor for the Immunotherapy journal. He added: “Using a detailed background on the clinical development of the first EMA approved biosimilar monoclonal antibody, this article creates a useful framework for consideration of these new drug options.”